Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALB | P02768 | 1/20 | 0.30 |
| ▸ | ALPG | P10696 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18159370 | 0.79 | SRC (0.46) | SRCERN1ALDH1A1LMNAMAPT | |
| SCHEMBL7347117 | 0.73 | DRD1 (0.56) | SRCDRD1ERN1ALDH1A1LMNA | |
| SCHEMBL30138925 | 0.71 | SRC (0.47) | SRCERN1ALDH1A1LMNAMAPT | |
| SCHEMBL2888296 | 0.69 | ERN1 (0.52) | SRCERN1ALDH1A1LMNAKDM4E | |
| SCHEMBL459167 | 0.69 | SRC (0.47) | SRCERN1ALDH1A1KDM4EGAA | |
| SCHEMBL18149272 | 0.68 | MAPT (0.33) | ALDH1A1LMNAMAPTGAA | |
| SCHEMBL18149152 | 0.68 | MAPT (0.35) | ALDH1A1LMNAMAPT | |
| SCHEMBL18145704 | 0.68 | ALDH1A1 (0.44) | SRCDRD1ERN1ALDH1A1LMNA | |
| SCHEMBL268706 | 0.68 | ALDH1A1 (0.52) | SRCERN1ALDH1A1LMNAMAPT | |
| SCHEMBL22867745 | 0.67 | ALDH1A1 (0.44) | SRCERN1ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160748-B2 | Indazolones as modulators of tnf signaling | ABBVIE INC. (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-03-29 | — | — | US | disclosed |
| US-20160304496-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304496-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304496-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| WO-2016168633-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304496-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, CD40, TNFRSF1A | SRC 191/4885DRD1 1662/4885ERN1 2145/4885 |
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, CD40, TNFRSF1A | SRC 191/4885DRD1 1662/4885ERN1 2145/4885 |
| US-10160748-B2 | Indazolones as modulators of tnf signaling | TNF, CD40, TNFRSF1A | SRC 191/4885DRD1 1662/4885ERN1 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.